AHCO vs. AMED, BTSG, ADUS, AVAH, EHAB, LHCG, CHE, OPCH, CRSP, and APLS
Should you be buying AdaptHealth stock or one of its competitors? The main competitors of AdaptHealth include Amedisys (AMED), BrightSpring Health Services (BTSG), Addus HomeCare (ADUS), Aveanna Healthcare (AVAH), Enhabit (EHAB), LHC Group (LHCG), Chemed (CHE), Option Care Health (OPCH), CRISPR Therapeutics (CRSP), and Apellis Pharmaceuticals (APLS). These companies are all part of the "medical" sector.
Amedisys (NASDAQ:AMED) and AdaptHealth (NASDAQ:AHCO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk, community ranking and dividends.
Amedisys has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, AdaptHealth has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.
Amedisys has higher earnings, but lower revenue than AdaptHealth. Amedisys is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amedisys had 3 more articles in the media than AdaptHealth. MarketBeat recorded 5 mentions for Amedisys and 2 mentions for AdaptHealth. AdaptHealth's average media sentiment score of 1.55 beat Amedisys' score of 0.33 indicating that Amedisys is being referred to more favorably in the media.
Amedisys received 418 more outperform votes than AdaptHealth when rated by MarketBeat users. However, 59.23% of users gave AdaptHealth an outperform vote while only 58.93% of users gave Amedisys an outperform vote.
94.4% of Amedisys shares are held by institutional investors. Comparatively, 82.7% of AdaptHealth shares are held by institutional investors. 1.8% of Amedisys shares are held by company insiders. Comparatively, 4.4% of AdaptHealth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Amedisys has a net margin of -0.91% compared to Amedisys' net margin of -21.45%. AdaptHealth's return on equity of 12.85% beat Amedisys' return on equity.
Amedisys presently has a consensus target price of $100.80, indicating a potential upside of 9.86%. AdaptHealth has a consensus target price of $12.42, indicating a potential upside of 10.86%. Given Amedisys' stronger consensus rating and higher possible upside, analysts plainly believe AdaptHealth is more favorable than Amedisys.
Summary
Amedisys beats AdaptHealth on 10 of the 18 factors compared between the two stocks.
Get AdaptHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for AHCO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AHCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AdaptHealth Competitors List
Related Companies and Tools
